[
  {
    "ts": "2025-11-28T12:01:00+00:00",
    "headline": "SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance",
    "summary": "SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® f",
    "url": "https://finance.yahoo.com/news/skyrizi-risankizumab-receives-positive-reimbursement-120100009.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e2efd97f-9691-3534-9c8c-26a736875513",
      "content": {
        "id": "e2efd97f-9691-3534-9c8c-26a736875513",
        "contentType": "STORY",
        "title": "SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance",
        "description": "",
        "summary": "SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® f",
        "pubDate": "2025-11-28T12:01:00Z",
        "displayTime": "2025-11-28T12:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/45ddc61cd4d2534722e8ee1951eb9d11",
          "originalWidth": 1437,
          "originalHeight": 1200,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n1fgLZblsBDNX0Mc5iPR2A--~B/aD0xMjAwO3c9MTQzNzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/45ddc61cd4d2534722e8ee1951eb9d11.cf.webp",
              "width": 1437,
              "height": 1200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZBFEhBP6maLLe2wL.BVmiA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/45ddc61cd4d2534722e8ee1951eb9d11.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/skyrizi-risankizumab-receives-positive-reimbursement-120100009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/skyrizi-risankizumab-receives-positive-reimbursement-120100009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]